USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Superlab FAR EAST Limited

USPTO PatentsView assignee record - 6 granted patents across 10 technology areas, active 2016–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

12.2

Avg claims per patent

+100%

5-year filing velocity

The verdict

Superlab holds 6 US patents across 10 technology areas, rank #43,037 of 50,000 tracked assignees.

#43,037
of 50,000 US assignees by volume: Top 76%
by Innovation Score (27.4/100): 12.2
avg claims per patent: +100%
filing velocity, last 5 yrs

Portfolio overview

Superlab FAR EAST Limited has been granted 6 US utility patents between 2016 and 2024, placing Superlab FAR EAST Limited at rank #43,037 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Superlab FAR EAST Limited is one of the more focused assignees in the PatentsView dataset. By volume, Superlab sits between SUNG JUNG Minute Industry Co., Ltd. (6 patents, rank #43,033) and SUSS Microtec Photonic Systems Inc. (6 patents, rank #43,041) - the closest US assignees by grant volume. The composite Innovation Score of 27.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 2 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Superlab FAR EAST Limited's 12.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Superlab FAR EAST Limited against peers pursuing similar technology classes.

SUNG JUNG Minute…

6
Sunia PTE

6
Sunpine AB

6
Sunsight Holdings

6
Suprema HQ

6
Surgisense

6
Suspension Systems

6
SUSS Microtec Pho…

6
Superlab FAR EAST ◀

6

What this shows Superlab holds 6 patents at rank #43,037, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Superlab

By rank, the assignees closest to #43,037 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Superlab's primary technology class.

Superlab's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

27 Top 76% higher than 24% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Superlab FAR EAST Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	16.7%
2018	1	16.7%
2020	3	50.0%
2024	1	16.7%

Which technologies does Superlab FAR EAST Limited patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 6

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 6

C07K - PEPTIDES 4

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 3

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 2

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

G16B - BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY 1

G16C - COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE 1

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1

Top 10 of 10 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#43,037

Across all tracked assignees

Innovation Score

27.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Superlab FAR EAST Limited hold?

Superlab FAR EAST Limited holds 6 US granted patents filed between 2016 and 2024, spanning 10 technology areas.

What is Superlab FAR EAST Limited's Innovation Score?

Superlab FAR EAST Limited has an Innovation Score of 27.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Superlab FAR EAST Limited focus on?

Superlab FAR EAST Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 10 CPC subclasses total.

Is Superlab FAR EAST Limited's patent filing rate increasing or decreasing?

Superlab FAR EAST Limited's recent filing velocity is +100% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Superlab FAR EAST Limited's patents?

Superlab FAR EAST Limited's patents average 12.2 claims each. This falls within the standard range, providing solid legal coverage.

How is the Superlab FAR EAST Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Superlab's 6 grants land it in the top 76% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Superlab ranks #43,037 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.